Bengaluru-based deep-tech neuroscience startup BrainSightAI has received $5 million in its pre-Series A funding led by IAN Alpha Fund, according to a company's statement. In the latest round, IvyCap Ventures, Silver Needle, alongwith existing investors also participated.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

The funding will help the startup achieving a significant milestone in BrainSightAI’s mission to revolutionize the diagnosis and treatment of complex brain disorders through its innovative neuroinformatics platform, VoxelBox, it said in the statement.

The funds will also be utilised to expand BrainSightAI’s presence in India, increasing its reach in Tier 1 cities and extend to Tier 2 cities. The company also plans to pursue FDA certification, opening access to the US and allied markets. 

Commenting on the investment, Priyank Garg, managing partner at IAN Alpha Fund said, "BrainSightAI’s mission to democratise access to personalized brain care is inspiring, and the technology they’ve built is a fundamental innovation in brain physiology. The connectomics platform, VoxelBox, has the potential to transform the way brain disorders are diagnosed and treated for all humanity. At IAN, we are thrilled to support such a purpose-driven company that combines deep-tech innovation with impactful healthcare solutions.”

Founded in 2019 by Laina Emmanuel and Rimjhim Agrawal, BrainSightAI claims to have collaboration with over 40 leading hospitals across India, particularly in neurosurgery and radiology departments, focusing on brain tumor cases. 

IAN Alpha Fund, a Rs 1,000 crore (US$125 million) SEBI-registered AIF Category II VC Fund, is the second Fund in IAN’s series of Funds. The Fund will explore opportunities in diverse sectors such as fintech, healthtech, cleantech, AI, deep tech, agritech, medtech, hardware and electronics, manufacturing, Web 3.0, Metaverse, Industry 4.0, SaaS, D2C, and other domains where innovation abounds.